All In Biotech

Drug Trial Radar · NCT04185246

A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

A Multicenter, Open-Label, Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Nov 4, 2019

Primary completion

Jul 1, 2020

Study completion Jul 1, 2020

Sponsor

Lead sponsor
Trust Bio-sonics, Inc.Industry
Sponsor type
Industry
Collaborators
StatPlus,Inc.
First posted
Dec 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

NH002 (Perflutren Lipid Microspheres) Injectable Suspension is an ultrasound contrast agent for use in patients with suboptimal echocardiograms to opacify the left ventricular (LV) chamber and to improve the delineation of the LV endocardial border. The primary objective of this study is to evaluate the safety and tolerability of 3 ascending doses of NH002.

Conditions

  • Cardiac Disease

Interventions

  • NH002 (Perflutren Lipid Microspheres) Injectable SuspensionDrug

    NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.

  • EchocardiogramDiagnostic test

    Each patient will undergo an unenhanced ultrasound examination and a NH002 contrast-enhanced examination on the same day.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 12-lead ECGsTime frame: From pre-injection to 60 minutes post injection
  2. Body TemperatureTime frame: From pre-injection to 120 minutes post injection
  3. Heart RateTime frame: From pre-injection to 120 minutes post injection
  4. Respiratory RateTime frame: From pre-injection to 120 minutes post injection
  5. Blood PressureTime frame: From pre-injection to 120 minutes post injection
  6. Thrombin Time (TT) and Activated Partial Thromboplastin Time (aPTT)Time frame: From pre-injection to 240 minutes post-injection
  7. Cardiac Troponin ITime frame: pre-injection and 240 minutes post-injection
  8. Oxygen Saturation by Pulse Oximetry (SpO2)Time frame: From pre-injection to 120 minutes post-injection
  9. Rate of Any Potential Adverse Allergic ReactionTime frame: From pre-injection to 240 minutes post-injection
  10. Cardiac Troponin TTime frame: pre-injection and 240 minutes post-injection

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Taipei Mackay Memorial Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.